The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis. Peripheral T-cell lymphomas (PTCL) are aggressive proliferative disorders of peripheral lymphocytes with severely unmet medical needs, as five-year patient survival rates remains at approximately 30%.
XENOTHERA has been a France 2030 prize winner for several years. The support of the Secrétariat Général pour l’Investissement (SGPI) and the Agence de l’Innovation en Santé (AIS) has enabled the company to progress in terms of pharmaceutical, clinical and industrial maturity. In particular, the ‘Capacity building’ component of France 2030 has enabled XENOTHERA to build its own biomanufacturing site in the Pays de la Loire region. The PALT24 project confirms this support. France 2030’s i-Demo call for projects aims to develop industrial and service companies in strategic markets that create value and drive competitiveness for the French and European economies. This €4 million funding will enable XENOTHERA to conduct the PALT1 clinical trial (NCT06495723), with the aim of obtaining early access authorisation in France and Europe by 2027.
XENOTHERA’s antibody is derived from its unique GH-pAb technology platform (glyco-humanized polyclonal antibodies). It has demonstrated potent anti-tumoral activity against cancer lymphocyte cell lines. It was granted an “orphan drug designation” from health authorities in both the United States (FDA) and Europe (EMA) for this indication.[1]
Odile Duvaux, President and Co-Founder of XENOTHERA, commented:
“This funding is both a critical enabler of this essential project for patients and a confirmation of the strategic importance of XENOTHERA’s approach, which is fully committed to developing and producing high-value biologics here at home. French companies must deliver the benefits of our research and scientific advancements to patients as close to home as possible. Once again, XENOTHERA’s teams can be proud of the landmark results achieved, which are the result of an unwavering commitment to patient care. I would like to thank the teams at the General Secretariat for Investment, who, through France 2030, have been longstanding supporters of our work, encouraging us to pursue our entrepreneurial approach within a socially and environmentally responsible project.”
About XENOTHERA:
Founded in 2014 by a team of renowned European scientists (Professors Soulillou, Bach, Cozzi, and Galli in France and Italy) under the presidency of Dr. Odile Duvaux, MD, PhD, XENOTHERA is a Nantes-based biotechnology company developing innovative therapeutic approaches with a focus on oncology and immunology, built on a unique glyco-humanized antibody technology platform. This platform combines advanced expertise in genetics and immunology.
XENOTHERA has a diverse product portfolio, including three clinical-stage assets. Its leading candidates are LIS1 in transplantation, XON7 in solid tumors, and LIS22 in onco-hematology. The company is rooted in the scientific and medical ecosystem of the Pays de la Loire region (France). Since its inception, XENOTHERA has raised €43 million, with funding from sources such as the Pays de la Loire Region, BPI France, the European EIC Fund, and private investors.
More information: www.xenothera.com
Follow XENOTHERA on social media: LinkedIn , X
The France 2030 investment plan
About France 2030 :
France 2030 is unprecedented in its scale: €54 billion is being invested so that our businesses, our schools, our universities and our research organizations fully succeed with their transitions in these strategic sectors. The challenge is to enable them to respond in a competitive way to the world’s future ecological and attractiveness challenges, and to showcase the future champions of our sectors of excellence. France 2030 is defined by two overarching objectives, which will see 50% of expenses given over to the decarbonization of the economy, and 50% to emerging key players, those at the forefront of innovation, without neglecting the environment (in the sense of the “Do No Significant
Harm” principle).
France 2030 is being implemented collectively: designed and deployed in consultation with economic, academic, local and European key players to establish strategic guidelines and decisive action. Project holders are invited to submit their entries via the current application process, which is a demanding and selective one, to benefit from state support.
France 2030 is being led by the French General Secretariat for Investment, in charge of France 2030, on behalf of the Prime Minister, and in partnership with the relevant government ministries.
France 2030 is being implemented by the French National Research Agency (ANR), the French Agency for Ecological Transition (ADEME), Bpifrance and the Caisse des Dépôts et consignation (CDC).
More information : france2030.gouv.fr | @SGPI_avenir
About the i-Demo program within France 2030
The i-Demo initiative supports the development of highly innovative, high-value products and services to strengthen France’s scientific and technological foundation. It also funds industrial or pre-industrial demonstrators of advanced-stage innovations (prototypes in representative environments, pilot lines).
Projects, whether collaborative or single-partner, have a minimum total expenditure of €4 million. Public support complies with European Union state aid regulations and may be provided as grants and/or repayable advances.
Press relations :
Akkanto
Carmen Borissova
+33(0)06 09 91 33 03
carmen.borissova@akkanto.fr / xenothera@akkanto.fr